BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Moreover, hypermethylation of miR-203 has been reported in chronic myeloid leukemia (CML), conferring a proliferative advantage to the tumor cells by inhibiting the oncogenic BCR-ABL fusion protein [12].